Spandan Chennamadhavuni Ph D
About
Spandan Chennamadhavuni Ph D is from Atlanta, Georgia, United States. Spandan works in the following industries: "Pharmaceutical Manufacturing". Spandan is currently Principal Scientist at Atea Pharmaceuticals, Inc, located in Boston, Massachusetts, United States. In Spandan's previous role as a Senior Staff Scientist at Emory University, Spandan worked in Greater Atlanta Area until Apr 2022. Prior to joining Emory University, Spandan was a Executive Committee Co-Chair at Emory Postdoctoral Association and held the position of Executive Committee Co-Chair at Greater Atlanta Area. Prior to that, Spandan was a Research Scientist at Harvard Medical School, based in Greater Boston Area from Jun 2014 to Sep 2015. Spandan started working as Research Scientist at Dana-Farber Cancer Institute in Greater Boston Area in Jun 2014. From Oct 2011 to Jul 2014, Spandan was CMLD Research Associate at Boston University, based in CMLD-BU & John A. Porco, Jr LAB. Prior to that, Spandan was a Graduate Research Assistant at Emory University, based in HUW ML DAVIES LAB from Jul 2008 to Dec 2011. Spandan started working as Graduate Research Assistant at State University of New York at Buffalo in HUW ML DAVIES LAB in Aug 2006.
You can find Spandan Chennamadhavuni Ph D's email on finalScout.com. FinalScout is a popular professional database with more than 500 million business professionals and over 200 million company profiles.
Spandan Chennamadhavuni Ph D's current jobs
Driving antiviral drug discovery programs.
Spandan Chennamadhavuni Ph D's past jobs
Design novel therapeutics targeting " ArmR" as potential antibacterial agents.
The Emory Postdoctoral Association (PDA), established in 2007, is an organization sponsored by the Emory School of Medicine (SOM) Office of Postdoctoral Education (OPE) and is dedicated to improving the postdoctoral experience for all fellows at Emory University. The executive committee provides leadership, organization, support, and continuity to the Postdoctoral Association (PDA). In formal settings, the co-chairs of the executive committee serve as the spokespersons on behalf of the PDA.
MALT1 INHIBITORS FOR THE TREATMENT OF CHEMO-RESISTANT ABC-DLBCL
MALT1 INHIBITORS FOR THE TREATMENT OF CHEMO-RESISTANT ABC-DLBCL
➢ Design & synthesize chemical libraries of bioactive complex "natural product based" chemotypes ➢ Discover, develop & optimize novel chemical methodologies, build libraries around novel chemotypes ➢ Design and synthesis of novel macrocyclic scaffolds based on the computational docking results ➢ Analyzed the pharmacological data for orally available macrocyclic drugs for a “Nature Chemical Biology” review article ➢ re-synthesizing small molecule NEMO inhibitor discovered in high throughput screening of entire CMLD compound collection & establishing structure-activity relationship (SAR) around spiroisoxazoline core structure. ➢ Established a methodology for the synthesis of diazepinedione core by utilizing a three-step cascade (double bond isomerization/Aza-Michael/lactamization) reaction
SYNTHESIS OF SMALL MOLECULE THERAPEUTICS UTILIZING RHODIUM CARBENOID CHEMISTRY
SYNTHESIS OF SMALL MOLECULE THERAPEUTICS UTILIZING RHODIUM CARBENOID CHEMISTRY
"Brønsted Acid-Catalyzed Imine Amidation" published in JACs, Cited 165 times as of 2014